Covered recipient · General Payments record
SUE ADAMS
Allopathic & Osteopathic Physicians Family Medicine
General Payments · PY2018–2024
$4,363.95
- Reported across 346 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $490.46 | 35 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Lilly USA, LLC | $160.50 | 12 |
| ABBVIE INC. | $135.96 | 12 |
| Acerta Pharma LLC | $72.17 | 4 |
| PFIZER INC. | $45.56 | 3 |
| Novo Nordisk AS | $40.67 | 2 |
| DEXCOM, INC. | $18.72 | 1 |
| Merck Sharp & Dohme Corporation | $16.88 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (35)
Sorted by paying entity, then date · as published by CMS
Program year 2024 201820192020202120222023
Record-level detail is published for PY2024; earlier years are summarised in
“By program year”.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $8.96 | 01/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103174856 | CMS |
| ABBVIE INC. | $8.74 | 02/28/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103174858 | CMS |
| ABBVIE INC. | $9.24 | 03/14/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103174860 | CMS |
| ABBVIE INC. | $9.77 | 03/27/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103174862 | CMS |
| ABBVIE INC. | $15.31 | 04/05/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103174864 | CMS |
| ABBVIE INC. | $20.38 | 04/05/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103174866 | CMS |
| ABBVIE INC. | $5.15 | 04/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103174868 | CMS |
| ABBVIE INC. | $6.32 | 04/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103174870 | CMS |
| ABBVIE INC. | $8.76 | 05/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103174872 | CMS |
| ABBVIE INC. | $9.60 | 06/05/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103174874 | CMS |
| ABBVIE INC. | $13.75 | 07/09/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103174876 | CMS |
| ABBVIE INC. | $19.98 | 08/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103174878 | CMS |
| AstraZeneca Pharmaceuticals LP | $15.72 | 02/01/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104546614 | CMS |
| AstraZeneca Pharmaceuticals LP | $16.66 | 08/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105281750 | CMS |
| AstraZeneca Pharmaceuticals LP | $14.54 | 08/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105234541 | CMS |
| AstraZeneca Pharmaceuticals LP | $25.25 | 10/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105532002 | CMS |
| Dexcom, Inc. | $18.72 | 09/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1153338837 | CMS |
| Lilly USA, LLC | $13.42 | 04/02/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135429433 | CMS |
| Lilly USA, LLC | $18.97 | 04/16/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135408919 | CMS |
| Lilly USA, LLC | $15.00 | 05/02/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135433639 | CMS |
| Lilly USA, LLC | $6.31 | 07/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135429431 | CMS |
| Lilly USA, LLC | $18.13 | 07/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135394501 | CMS |
| Lilly USA, LLC | $7.37 | 07/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135394499 | CMS |
| Lilly USA, LLC | $9.36 | 07/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135419115 | CMS |
| Lilly USA, LLC | $13.40 | 08/26/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135351275 | CMS |
| Lilly USA, LLC | $15.26 | 09/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135433637 | CMS |
| Lilly USA, LLC | $16.28 | 09/30/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135419117 | CMS |
| Lilly USA, LLC | $12.91 | 10/28/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135351277 | CMS |
| Lilly USA, LLC | $14.09 | 11/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135408921 | CMS |
| Merck Sharp & Dohme LLC | $16.88 | 09/09/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1141955575 | CMS |
| Novo Nordisk Inc | $17.84 | 08/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097768847 | CMS |
| Novo Nordisk Inc | $22.83 | 10/07/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097351198 | CMS |
| PFIZER INC. | $14.95 | 04/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131353673 | CMS |
| PFIZER INC. | $14.92 | 07/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131777318 | CMS |
| PFIZER INC. | $15.69 | 09/30/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1132107302 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2020, 2021, 2022, 2023, 2024
- Source files
- Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.